Global Autoimmune Gastrointestinal Dysmotility Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Autoimmune Gastrointestinal Dysmotility Market Segmentation, By Treatment (Plasma Exchange, Medications, and Immunotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others) - Industry Trends and Forecast to 2032

Autoimmune Gastrointestinal Dysmotility Market Size

• The global autoimmune gastrointestinal dysmotility market size was valued at USD 39.45 billion in 2024 and is expected to reach USD 155.47 billion by 2032, at a CAGR of 18.70% during the forecast period
• The market growth is largely fueled by the increasing prevalence of autoimmune gastrointestinal disorders, advancements in diagnostic technologies, and growing awareness of specialized treatment options, leading to heightened adoption of autoimmune gastrointestinal dysmotility therapies in both hospital and outpatient settings
• Furthermore, rising patient demand for effective, targeted, and personalized treatment regimens is driving the development and uptake of innovative autoimmune gastrointestinal dysmotility solutions, thereby significantly boosting the industry's growth

Autoimmune Gastrointestinal Dysmotility Market Analysis

• The rising prevalence of autoimmune gastrointestinal dysmotility disorders is driving the demand for innovative diagnostic tools, personalized treatment plans, and advanced therapeutic solutions. These interventions are increasingly essential in hospitals, specialty clinics, and research centers for managing complex gastrointestinal motility disorders, improving patient outcomes, and reducing complications
• The escalating demand for autoimmune gastrointestinal dysmotility treatments is primarily fueled by increasing awareness of gastrointestinal health, growing prevalence of related autoimmune conditions, and advancements in diagnostic and therapeutic technologies. Enhanced patient access to healthcare services and early diagnosis programs are further supporting market growth
• North America dominated the autoimmune gastrointestinal dysmotility market with the largest revenue share of 41.5% in 2024, supported by advanced healthcare infrastructure, high patient awareness, and strong adoption of innovative diagnostic and treatment protocols. The U.S. is witnessing substantial growth due to increasing prevalence of autoimmune gastrointestinal disorders, robust clinical research activities, and initiatives promoting early intervention and specialized care
• Asia-Pacific is expected to be the fastest-growing region in the autoimmune gastrointestinal dysmotility market during the forecast period, with a projected CAGR of 23% from 2025 to 2032. Growth is driven by rapid urbanization, rising healthcare awareness, expanding hospital networks, and government initiatives focused on early diagnosis and management of autoimmune disorders in countries such as India, China, and Japan
• The Medications segment dominated the autoimmune gastrointestinal dysmotility market with a market revenue share of 46% in 2024, driven by the widespread use of pharmacological therapies such as prokinetic agents, anti-inflammatory drugs, and immunosuppressants to manage disease symptoms and improve gastrointestinal motility

Report Scope and Autoimmune Gastrointestinal Dysmotility Market Segmentation  

Autoimmune Gastrointestinal Dysmotility Market Trends

Rising Focus on Early Diagnosis and Targeted Therapeutics

• A significant and accelerating trend in the global autoimmune gastrointestinal dysmotility (AGID) market is the growing emphasis on early diagnosis and the development of targeted therapeutic interventions. Enhanced awareness among clinicians and patients is driving timely identification of AGID, which is critical to prevent complications such as severe gastrointestinal dysmotility, malnutrition, and secondary autoimmune disorders
• Diagnostic advancements, including high-resolution manometry, antibody profiling, and imaging techniques, are enabling more precise detection of AGID. This allows healthcare providers to distinguish between primary autoimmune disorders and secondary causes of gastrointestinal dysfunction, supporting tailored treatment plans
• There is an increasing focus on immunomodulatory therapies, prokinetic agents, and nutritional support to manage symptoms effectively while addressing underlying autoimmune mechanisms. Clinical trials and research are continuously contributing to the expansion of the therapeutic arsenal available for AGID
• Multidisciplinary approaches involving gastroenterologists, immunologists, dietitians, and rehabilitation specialists are becoming more common, helping patients achieve better symptom management and improved quality of life. Integrated care models are also facilitating patient monitoring and long-term follow-up
• Pharmaceutical and biotechnology companies are actively investing in the development of novel drugs, biologics, and precision medicine approaches, aimed at reducing inflammation, improving gut motility, and preventing disease progression
• The trend toward increased patient and physician awareness, combined with innovations in diagnostics and therapeutics, is driving robust growth in the AGID market across both hospital and outpatient care settings. This is reshaping treatment paradigms and expanding market opportunities globally

Autoimmune Gastrointestinal Dysmotility Market Dynamics

Driver

Growing Need Due to Rising Awareness and Early Diagnosis

• The increasing prevalence of gastrointestinal autoimmune disorders, coupled with rising awareness among patients and healthcare professionals, is a significant driver for the heightened demand for effective autoimmune gastrointestinal dysmotility (AGID) treatments. Early diagnosis is critical to managing disease progression, improving gut motility, and reducing complications

  • For instance, in April 2024, a study published in BMC Gastroenterology highlighted advancements in high-resolution manometry and serological testing, enabling more precise identification of AGID and differentiation from other gastrointestinal disorders. Such innovations by key research institutions are expected to drive market growth over the forecast period

• As patients and clinicians increasingly recognize the impact of autoimmune dysmotility on nutrition, quality of life, and systemic health, the demand for comprehensive diagnostic and management solutions is rising steadily. This includes therapeutic interventions, nutritional support, and patient monitoring strategies
• Furthermore, the growing emphasis on multidisciplinary care, involving gastroenterologists, immunologists, dietitians, and rehabilitation specialists, is making integrated treatment approaches a key component of disease management, improving outcomes and patient adherence
• The trend toward personalized medicine, targeted therapies, and proactive symptom management is propelling the adoption of innovative treatment regimens in both hospital and home care settings. Additionally, patient education and awareness campaigns contribute to earlier intervention and better management of AGID

Restraint/Challenge

Limited Awareness, High Costs, and Complex Treatment Protocols

• Limited awareness about autoimmune gastrointestinal disorders among certain patient populations poses a challenge to early diagnosis and treatment adoption. Misdiagnosis or delayed intervention can exacerbate disease progression, increasing the burden on healthcare systems

  • For instance, despite advances in diagnostic techniques, patients in remote or underserved regions often face delayed access to specialists, reducing timely treatment adoption and effective symptom management

• High costs associated with advanced diagnostic tests, biologic therapies, and long-term treatment regimens can be a barrier for many patients, particularly in developing regions or among uninsured populations. Even with insurance coverage, out-of-pocket expenses for complex therapies may limit adoption
• Treatment of AGID often requires multidisciplinary coordination, dietary adjustments, and continuous monitoring, which can be resource-intensive and challenging to implement consistently in outpatient or home care settings
• Overcoming these challenges through increased patient and clinician awareness, affordable diagnostic and therapeutic options, and simplified treatment protocols will be vital for sustained growth in the autoimmune gastrointestinal dysmotility market over the forecast period

Autoimmune Gastrointestinal Dysmotility Market Scope

The market is segmented on the basis of treatment, and distribution channel.

• By Treatment

On the basis of treatment, the autoimmune gastrointestinal dysmotility market is segmented into Plasma Exchange, Medications, and Immunotherapy. The Medications segment dominated the largest market revenue share of 46% in 2024, driven by the widespread use of pharmacological therapies such as prokinetic agents, anti-inflammatory drugs, and immunosuppressants to manage disease symptoms and improve gastrointestinal motility. Medications are preferred for their ease of administration, established clinical efficacy, and availability across hospital and retail pharmacies, making them accessible for both acute and chronic conditions.

Plasma Exchange is anticipated to witness the fastest CAGR of 12.5% from 2025 to 2032, as it offers targeted removal of autoantibodies and immune complexes, providing rapid symptom relief for severe or refractory cases. The adoption of plasma exchange is fueled by increasing awareness among healthcare providers, improved procedural protocols, and its integration into specialized treatment centers. Immunotherapy is gaining traction due to advancements in biologics, monoclonal antibodies, and personalized immune-targeted therapies. Its growth is supported by rising investment in clinical research, growing understanding of autoimmune mechanisms, and the need for long-term disease management strategies. Hospitals and specialty clinics are increasingly incorporating immunotherapy into treatment regimens, highlighting its critical role in comprehensive patient care.

• By Distribution Channel

On the basis of distribution channel, the autoimmune gastrointestinal dysmotility market is segmented into hospital pharmacy, retail pharmacy, online pharmacies, and others. The hospital pharmacy segment accounted for the largest market revenue share of 49% in 2024, reflecting the centralized procurement of specialized treatments, high patient footfall in hospitals, and the availability of complex therapies such as plasma exchange and immunotherapy. Hospital pharmacies ensure quality, compliance, and accessibility for patients requiring regular or emergency treatment.

Retail Pharmacies are witnessing steady growth due to increasing consumer preference for convenient access to medications for home-based treatment, coupled with extended operating hours and widespread urban coverage. The Online Pharmacies segment is expected to witness the fastest CAGR of 14% from 2025 to 2032, propelled by digitalization, e-commerce penetration, home delivery convenience, and rising awareness of chronic gastrointestinal conditions. Patients increasingly prefer online channels for privacy, accessibility, and price comparison. The Others segment, including specialized distributors and government supply chains, is expanding gradually, supporting regional outreach, rural accessibility, and public health initiatives, particularly in emerging economies.

Autoimmune Gastrointestinal Dysmotility Market Regional Analysis

• North America dominated the autoimmune gastrointestinal dysmotility market with the largest revenue share of 41.5% in 2024
• Supported by advanced healthcare infrastructure, high patient awareness, and strong adoption of innovative diagnostic and treatment protocols
• The region benefits from a large patient base, well-established clinical research networks, and widespread access to specialized gastroenterology care, contributing to early diagnosis, improved disease management, and better patient outcomes

U.S. Autoimmune Gastrointestinal Dysmotility Market Insight

The U.S. autoimmune gastrointestinal dysmotility market captured the largest revenue share within North America in 2024, driven by the rising prevalence of autoimmune gastrointestinal disorders, growing clinical research activities, and implementation of specialized care programs. Increased investments in therapeutic development, availability of advanced diagnostic facilities, and initiatives promoting early intervention are enabling timely treatment and improving quality of life for patients. Additionally, robust healthcare infrastructure and high awareness among clinicians and patients support market expansion across hospital and outpatient care settings.

Europe Autoimmune Gastrointestinal Dysmotility Market Insight

The Europe autoimmune gastrointestinal dysmotility market is projected to maintain steady growth in the autoimmune gastrointestinal dysmotility market, supported by comprehensive healthcare systems, rising patient awareness, and adoption of standardized treatment guidelines. Countries such as Germany and the U.K. are driving growth, with well-developed diagnostic networks, government support for healthcare innovation, and increasing focus on early detection and management of autoimmune gastrointestinal disorders.

U.K. Autoimmune Gastrointestinal Dysmotility Market Insight

The U.K. autoimmune gastrointestinal dysmotility market is expected to grow at a significant CAGR during the forecast period, fueled by increasing prevalence of autoimmune gastrointestinal disorders and rising emphasis on early diagnosis and treatment. Structured healthcare delivery, strong hospital infrastructure, and active clinical research programs enable better access to advanced therapies, contributing to effective management of autoimmune gastrointestinal dysmotility.

Germany Autoimmune Gastrointestinal Dysmotility Market Insight

The Germany autoimmune gastrointestinal dysmotility market is anticipated to expand at a considerable CAGR, driven by increasing patient awareness, strong healthcare infrastructure, and investment in research and development of novel therapeutic options. The focus on evidence-based treatment, availability of specialized gastroenterology centers, and rising preventive care initiatives support market growth across both hospital and outpatient settings.

Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market Insight

The Asia-Pacific autoimmune gastrointestinal dysmotility market is expected to be the fastest-growing region in the autoimmune gastrointestinal dysmotility market, with a projected CAGR of 23% from 2025 to 2032. Growth is fueled by rapid urbanization, rising healthcare awareness, expanding hospital networks, and government initiatives focused on early diagnosis and management of autoimmune disorders. Countries such as India, China, and Japan are leading regional growth, supported by increased access to specialized care, patient education programs, and adoption of advanced diagnostics and treatment protocols.

Japan Autoimmune Gastrointestinal Dysmotility Market Insight

The Japan autoimmune gastrointestinal dysmotility market is gaining momentum due to its high-tech healthcare environment, aging population, and increasing prevalence of autoimmune gastrointestinal disorders. Strong hospital infrastructure, availability of advanced diagnostics, and high patient awareness enable early intervention and effective disease management, contributing to steady market growth.

China Autoimmune Gastrointestinal Dysmotility Market Insight

The China autoimmune gastrointestinal dysmotility market accounted for the largest market revenue share in Asia-Pacific in 2024, driven by rapid urbanization, expanding middle-class population, and rising prevalence of autoimmune gastrointestinal disorders. The growth is supported by government healthcare initiatives, expansion of specialized treatment centers, and increased focus on early diagnosis, enabling better patient outcomes and higher treatment adoption rates.

India Autoimmune Gastrointestinal Dysmotility Market Insight

The India autoimmune gastrointestinal dysmotility market is emerging as one of the fastest-growing markets globally for autoimmune gastrointestinal dysmotility, driven by rising patient awareness, government programs promoting early detection, and expanding hospital networks. Growing clinical research activities, improved access to gastroenterology specialists, and adoption of advanced diagnostics and therapeutic interventions are expected to sustain high market growth throughout the forecast period.

Autoimmune Gastrointestinal Dysmotility Market Share

The autoimmune gastrointestinal dysmotility industry is primarily led by well-established companies, including:

• AbbVie Inc. (U.S.)
• GSK plc (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chugai Pharmaceutical Co. Ltd. (Japan)
• Zeria Pharmaceutical Co. Ltd. (Israel)
• Ironwood Pharmaceuticals Inc. (U.S.)
• Vanda Pharmaceuticals Inc. (U.S.)
• Dr. Falk Pharma GmbH (Germany)
• Rose Pharma LLC (U.S.)
• Parvus Therapeutics Inc. (U.S.)
• CinDome Pharma Inc. (U.S.)
• Neurogastrx Inc. (U.S.)
• Renexxion LLC (U.S.)
• ISOThrive Inc. (U.S.)
• Ambrose Healthcare Inc. (U.S.)
• AnTolRx Inc. (U.S.)
• Enteralia Bioscience S.r.l. (Italy)
• Immunic Inc. (U.S.)
• Mozart Therapeutics Inc. (U.S.)

Latest Developments in Global Autoimmune Gastrointestinal Dysmotility Market

• In April 2022, TheraCell Inc., a leading allograft solution company, today announced that Isto Biologics have acquired it, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies
• In July 2022, a study published in Neurogastroenterology & Motility reported a case where a 17-year-old female developed AGID following a SARS-CoV-2 infection. She experienced severe gastrointestinal symptoms, including intractable nausea and early satiety, leading to the need for nasogastric and nasoduodenal tube feedings, and eventually total parenteral nutrition. After intravenous immunoglobulin (IVIG) treatment, her symptoms improved dramatically, allowing her to tolerate a full oral diet. This case highlights the potential of immunotherapy in managing AGID, especially in the context of post-viral syndromes.
• In July 2021, a case report published in ACG Case Reports Journal detailed the occurrence of AGID in a patient with HIV. The condition was managed with a combination of methylprednisolone and pyridostigmine, suggesting that immunosuppressive and cholinergic therapies may be effective in treating AGID in certain patient populations. This report contributes to the expanding knowledge of AGID's pathophysiology and treatment options

SKU-69185